Loading...
Market
What will Novo Nordisk's stock price be at the end of Q2 2025?
2
Resolution / Starting Odds
Below $100 • 25%
$100 to $125 • 25%
$126 to $150 • 25%
Above $150 • 25%
Public stock market data from exchanges such as NASDAQ or Bloomberg
Story
Novo Nordisk Shares Drop 27% as CagriSema Misses Weight Loss Target in Phase 3 Trial
Dec 20, 2024, 11:00 AM
Novo Nordisk, Europe's largest company, saw its shares plummet by up to 27%, marking its worst trading day since April 2002, after its experimental obesity drug CagriSema failed to meet weight loss expectations in the Phase 3 REDEFINE 1 trial. The trial showed that patients treated with CagriSema achieved a 22.7% weight reduction after 68 weeks, falling short of the anticipated 25%. Additionally, only 57% of patients reached the highest dose after 68 weeks. Comparatively, patients receiving semaglutide 2.4 mg and cagrilintide 2.4 mg experienced weight losses of 16.1% and 11.8%, respectively, while the placebo group lost 2.3%. The disappointing results led to a significant sell-off, with the stock losing its 200-day moving average at $125 and trading 48% below its June high. Competitors such as Eli Lilly and Viking Therapeutics saw their shares rise in response to the news.
View original story
Similar markets
Below $200 • 25%
$200 - $250 • 25%
$250 - $300 • 25%
Above $300 • 25%
Yes • 50%
No • 50%
Increase by more than 5% • 25%
Change within +/- 5% • 25%
Decrease by 5-10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Outperform significantly • 25%
Outperform slightly • 25%
Underperform • 25%
Match performance • 25%
Significant increase • 25%
Moderate increase • 25%
No significant change • 25%
Decrease • 25%
